Q-omics provides the consensus-scored CHTF18 profile across patient tissues and cancer cell-line models. CHTF18 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CHTF18 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, CHTF18 protein abundance shows 35,133 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where CHTF18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHTF18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHTF18 survival associations across molecular data types. CHTF18 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHTF18 RNA expression–survival associations across cancer types. High CHTF18 expression shows unfavorable associations in ACC, KIRC, MESO and LIHC, but favorable associations in HNSC and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CHTF18 RNA expression.
This table summarizes CHTF18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CHTF18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHTF18 shows higher tumor expression in COAD, HNSC, KIRP, KIRC, BLCA and STAD. The COAD box plot shows higher CHTF18 RNA expression in tumor versus normal tissue (log2 FC = +2.134, t-test p < 0.001).
This table shows molecular features associated with CHTF18 in patient tissues and cancer cell lines. In patient samples, CHTF18 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CHTF18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
